Valeant Pharmaceuticals International (VRX) has risen sharply, recording gains of 3.72% in the past 4 weeks. However, the stock has corrected -1.68% in the past 1 week, providing a good buying opportunity on dips. Valeant Pharmaceuticals International (VRX) : During the past 4 weeks, traders have been relatively bearish on Valeant Pharmaceuticals International (VRX), hence the stock is down -0.62% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -3.13% relative to the S&P 500. The stock has recorded a 20-day Moving Average of 5.57% and the 50-Day Moving Average is 8.78%.
Valeant Pharmaceuticals International (NYSE:VRX): The stock opened at $22.89 on Friday but the bulls could not build on the opening and the stock topped out at $23.13 for the day. The stock traded down to $22.41 during the day, due to lack of any buying support eventually closed down at $22.86 with a loss of -0.70% for the day. The stock had closed at $23.02 on the previous day. The total traded volume was 19,623,839 shares.
The company Insiders own 8.62% of Valeant Pharmaceuticals International shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by 9.12% . Institutional Investors own 78.85% of Valeant Pharmaceuticals International shares. During last six month period, the net percent change held by insiders has seen a change of 9.12%. In a related news, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the Director of Valeant Pharmaceuticals International, Inc., Ross Thomas W. Sr., had purchased 4,000 shares in a transaction dated on June 13, 2016. The transaction was executed at $24.4 per share with total amount equaling $97,600.
Valeant Pharmaceuticals International, Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: developed markets and emerging markets. The Companys developed markets segment consists of sales in the United States of pharmaceutical products, OTC products, and medical device products. The Companys Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals, OTC products, and medical device products.